The Europe fluorescent immunoassay market is expected to grow from US$ 781.27 million in 2021 to US$ 1,090.71 million by 2028; it is estimated to grow at a CAGR of 4.9% from 2021 to 2028.
Chronic diseases and conditions are rising across the region. The need for expensive chronic care is growing, placing significant demands on healthcare systems. The rise in the aging population and shifts in societal behavior contribute to a steady rise in these common and costly long-term health issues. The middle class is growing; thus, with the rise in urbanization, people are adopting a more sedentary lifestyle. This is driving obesity rates and cases of diseases such as diabetes. Chronic kidney disease (CKD) is the 14th leading cause of death and is responsible for 1.2 million deaths each year. The growing incidence of CKD is primarily associated with lifestyle disorders such as hypertension, cardiovascular disease, hormonal imbalances, and diabetes. Early detection and treatment of CKD are crucial, as progressive CKD is associated with unfortunate clinical consequences, such as end-stage kidney disease (ESKD), cardiovascular diseases, and increased mortality. The diagnosis, prognosis, and control of CKD are based on understanding the glomerular filtration rate (GFR). Cystatin-C is a better GFR marker than the commonly used creatinine. The fluorescence lateral flow immunoassay was developed and optimized to estimate the cystatin-C value to calculate the GFR.
The COVID-19 pandemic highlighted the need for rapid and accurate nucleic acid detection at the point-of-care. Further, fluorescence-based quantitative reverse transcription PCR (RT-qPCR) has high sensitivity and specificity, but turnaround times can be extended in part (ranging from hours to days) due to the need for nucleic acid purification and amplification. In addition, most people infected with SARS-CoV-2 develop mild or no symptoms. Therefore, there is an urgent need to develop rapid, simple, and high-throughput assays for the detection of nucleic acids. A standard fluorescence immunoassay system is a multiparametric, random access system that provides accurate and reliable diagnostic results. It is a system capable of performing qualitative and quantitative analyses of infections, respiratory diseases, and chronic diseases. A convenient user interface and laboratory information system (LIS)/hospital information system (HIS) connectivity save valuable time, and the analyzer automatically reads and interprets the results. A cut-off index provides a good reference point for medical decision-making. Therefore, there is a growing need for fluorescent immunoassays owing to the rising number of chronic diseases across the region.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe fluorescent immunoassay market at a notable CAGR during the forecast period.
Abbott, BD, bioMerieux SA, Danaher, F. Hoffmann-La Roche Ltd., Ortho Clinical Diagnostics Holdings plc, Quidel Corporation, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc. are among the leading companies operating in the Europe fluorescent immunoassay market.
Chronic diseases and conditions are rising across the region. The need for expensive chronic care is growing, placing significant demands on healthcare systems. The rise in the aging population and shifts in societal behavior contribute to a steady rise in these common and costly long-term health issues. The middle class is growing; thus, with the rise in urbanization, people are adopting a more sedentary lifestyle. This is driving obesity rates and cases of diseases such as diabetes. Chronic kidney disease (CKD) is the 14th leading cause of death and is responsible for 1.2 million deaths each year. The growing incidence of CKD is primarily associated with lifestyle disorders such as hypertension, cardiovascular disease, hormonal imbalances, and diabetes. Early detection and treatment of CKD are crucial, as progressive CKD is associated with unfortunate clinical consequences, such as end-stage kidney disease (ESKD), cardiovascular diseases, and increased mortality. The diagnosis, prognosis, and control of CKD are based on understanding the glomerular filtration rate (GFR). Cystatin-C is a better GFR marker than the commonly used creatinine. The fluorescence lateral flow immunoassay was developed and optimized to estimate the cystatin-C value to calculate the GFR.
The COVID-19 pandemic highlighted the need for rapid and accurate nucleic acid detection at the point-of-care. Further, fluorescence-based quantitative reverse transcription PCR (RT-qPCR) has high sensitivity and specificity, but turnaround times can be extended in part (ranging from hours to days) due to the need for nucleic acid purification and amplification. In addition, most people infected with SARS-CoV-2 develop mild or no symptoms. Therefore, there is an urgent need to develop rapid, simple, and high-throughput assays for the detection of nucleic acids. A standard fluorescence immunoassay system is a multiparametric, random access system that provides accurate and reliable diagnostic results. It is a system capable of performing qualitative and quantitative analyses of infections, respiratory diseases, and chronic diseases. A convenient user interface and laboratory information system (LIS)/hospital information system (HIS) connectivity save valuable time, and the analyzer automatically reads and interprets the results. A cut-off index provides a good reference point for medical decision-making. Therefore, there is a growing need for fluorescent immunoassays owing to the rising number of chronic diseases across the region.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe fluorescent immunoassay market at a notable CAGR during the forecast period.
Europe Fluorescent Immunoassay Market Segmentation
The Europe fluorescent immunoassay market is segmented into product type, application, end user, and country. Based on product type, the market is segmented into ELISA, rapid lateral flow immunoassay, and others. The ELISA segment dominated the market in 2021 and is expected to be fastest growing during forecast period. Based on application, the market is segmented into infectious diseases, oncology, cardiovascular diseases, and others. The infectious disease segment dominated the market in 2021 and is expected to be fastest growing during forecast period. Based on end user, the market is segmented into hospitals & clinics, diagnostic centers, pharmaceutical & biotechnology companies, academic & research institutes, and others. The hospitals and clinics segment dominated the market in 2021 and is expected to be fastest growing during forecast period. Based on country, the Europe fluorescent immunoassay market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe.Abbott, BD, bioMerieux SA, Danaher, F. Hoffmann-La Roche Ltd., Ortho Clinical Diagnostics Holdings plc, Quidel Corporation, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc. are among the leading companies operating in the Europe fluorescent immunoassay market.
Table of Contents
1. Introduction1.1 Study Scope
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Fluorescent Immunoassay Market - By Product Type
1.3.2 Europe Fluorescent Immunoassay Market - By Application
1.3.3 Europe Fluorescent Immunoassay Market - By End User
1.3.4 Europe Fluorescent Immunoassay Market - By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Fluorescent Immunoassay Market - Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
4.3 Expert Opinions
5. Europe Fluorescent Immunoassay Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Chronic Diseases
5.1.2 Increasing Demand for Cell Therapies
5.2 Market Restraints
5.2.1 Disadvantages of Fluorescent Immunoassays
5.3 Market Opportunities
5.3.1 Extensive Usage in Cancer Diagnostics
5.4 Future Trends
5.4.1 Increase in Development of Fluorescent Dyes and Instruments
5.5 Impact Analysis
6. Fluorescent Immunoassay Market - Europe Analysis
6.1 Europe Fluorescent Immunoassay Marker Revenue Forecast and Analysis
7. Europe Fluorescent Immunoassay Market Analysis - By Product Type
7.1 Overview
7.2 Europe Fluorescent Immunoassay Market Share by Product Type - 2021 & 2028 (%)
7.3 ELISA
7.3.1 Overview
7.3.2 ELISA: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
7.4 Rapid Lateral Flow Immunoassay
7.4.1 Overview
7.4.2 Rapid Lateral Flow Immunoassay: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
8. Europe Fluorescent Immunoassay Market Analysis - By Application
8.1 Overview
8.2 Europe Fluorescent Immunoassay Market Share by Application - 2021 & 2028 (%)
8.3 Infectious Diseases
8.3.1 Overview
8.3.2 Infectious Diseases: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
8.4 Oncology
8.4.1 Overview
8.4.2 Oncology: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
8.5 Cardiovascular Disease
8.5.1 Overview
8.5.2 Cardiovascular Disease: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
9. Europe Fluorescent Immunoassay Market Analysis - By End User
9.1 Overview
9.2 Europe Fluorescent Immunoassay Market Share by End User - 2021 & 2028 (%)
9.3 Hospitals & Clinics
9.3.1 Overview
9.3.2 Hospitals & Clinics: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
9.4 Diagnostic Centers
9.4.1 Overview
9.4.2 Diagnostic Centers: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
9.5 Pharmaceutical & Biotechnology Companies
9.5.1 Overview
9.5.2 Pharmaceutical & Biotechnology Companies: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
9.6 Academic & Research Institutes
9.6.1 Overview
9.6.2 Academic & Research Institutes: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
9.7 Others
9.7.1 Overview
9.7.2 Others: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
10. Europe Fluorescent Immunoassay Market Analysis - By Country
10.1 Overview
10.1.1 Europe Fluorescent Immunoassay Market Revenue and Forecasts to 2028, By Country (%)
10.1.1.1 Germany: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD million)
10.1.1.1.1 Overview
10.1.1.1.2 Germany: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)
10.1.1.1.3 Germany: Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
10.1.1.1.4 Germany: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
10.1.1.1.5 Germany: Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
10.1.1.2 UK: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD million)
10.1.1.2.1 Overview
10.1.1.2.2 UK: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)
10.1.1.2.3 UK: Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
10.1.1.2.4 UK: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
10.1.1.2.5 UK: Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
10.1.1.3 France: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD million)
10.1.1.3.1 Overview
10.1.1.3.2 France: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)
10.1.1.3.3 France: Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
10.1.1.3.4 France: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
10.1.1.3.5 France: Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
10.1.1.4 Italy: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD million)
10.1.1.4.1 Overview
10.1.1.4.2 Italy: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)
10.1.1.4.3 Italy: Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
10.1.1.4.4 Italy: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
10.1.1.4.5 Italy: Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
10.1.1.5 Spain: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD million)
10.1.1.5.1 Overview
10.1.1.5.2 Spain: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)
10.1.1.5.3 Spain: Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
10.1.1.5.4 Spain: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
10.1.1.5.5 Spain: Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
10.1.1.6 Rest of Europe: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Europe: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)
10.1.1.6.3 Rest of Europe: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
10.1.1.6.4 Rest of Europe: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
10.1.1.6.5 Rest of Europe: Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
11. Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 F. Hoffmann-La Roche Ltd.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Thermo Fisher Scientific Inc.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Abbott
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 BD
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Danaher
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 bioMerieux SA
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Sysmex Corporation
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Siemens AG
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Ortho Clinical Diagnostics Holdings plc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Quidel Corporation
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About the Publisher
13.2 Glossary of Terms
List of Figures
Figure 1. Europe Fluorescent Immunoassay Market Segmentation
Figure 2. Europe Fluorescent Immunoassay Market - By Country
Figure 3. Europe Fluorescent Immunoassay Market Overview
Figure 4. Europe Fluorescent Immunoassay Market, By Product Type
Figure 5. Europe Fluorescent Immunoassay Market, By Country
Figure 6. Europe PEST Analysis
Figure 7. Europe Fluorescent Immunoassay Market Impact Analysis of Driver and Restraints
Figure 8. Europe Fluorescent Immunoassay Market - Revenue Forecast and Analysis
Figure 9. Europe Fluorescent Immunoassay Market Share by Product Type - 2021 & 2028 (%)
Figure 10. Europe ELISA: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 11. Europe Rapid Lateral Flow Immunoassay: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 12. Europe Others: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 13. Europe Fluorescent Immunoassay Market Share by Application - 2021 & 2028 (%)
Figure 14. Europe Infectious Diseases: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 15. Europe Oncology: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 16. Europe Cardiovascular Disease: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 17. Europe Others: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 18. Europe Fluorescent Immunoassay Market Share by End User - 2021 & 2028 (%)
Figure 19. Europe Hospitals & Clinics: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 20. Europe Diagnostic Centers: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 21. Europe Pharmaceutical & Biotechnology Companies: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 22. Europe Academic & Research Institutes: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 23. Europe Others: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 24. Europe Fluorescent Immunoassay Market Revenue Overview, by Country, 2021 (US$ Million)
Figure 25. Europe Fluorescent Immunoassay Market Revenue and Forecasts to 2028, By Country (%)
Figure 26. Germany: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)
Figure 27. UK: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)
Figure 28. France: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)
Figure 29. Italy: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)
Figure 30. Spain: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)
Figure 31. Rest of Europe: Fluorescent Immunoassay Market Revenue and Forecasts to 2028 (USD Million)List of Tables
Table 1. Europe Fluorescent Immunoassay Market -Revenue and Forecast to 2028 (USD Million)
Table 2. Germany: Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
Table 3. Germany: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
Table 4. Germany: Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
Table 5. UK: Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
Table 6. UK: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
Table 7. UK: Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
Table 8. France: Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
Table 9. France: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
Table 10. France: Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
Table 11. Italy: Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
Table 12. Italy: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
Table 13. Italy: Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
Table 14. Spain: Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
Table 15. Spain: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
Table 16. Spain: Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
Table 17. Rest of Europe: Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
Table 18. Rest of Europe: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
Table 19. Rest of Europe: Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
Table 20. Organic Developments
Table 21. Inorganic Developments
Table 22. Glossary of Terms
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott
- BD
- bioMerieux SA
- Danaher
- F. Hoffmann-La Roche Ltd.
- Ortho Clinical Diagnostics Holdings plc
- Quidel Corporation
- Siemens AG
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 168 |
| Published | August 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 781.27 Million |
| Forecasted Market Value ( USD | $ 1090.71 Million |
| Compound Annual Growth Rate | 4.9% |
| Regions Covered | Europe |
![Immunodiagnostics Market Forecast to 2030 - Global Analysis by Product [Enzyme-Linked Immunosorbent Assays, Chemiluminescence Immunoassays, Radioimmunoassays, and Others], Clinical Indication, End User, and Geography - Product Image](http://www.researchandmarkets.com/product_images/12371/12371704_60px_jpg/immunodiagnostics_market.jpg)
